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ABSTRACT 
18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG 
PET/CT) is potentially applicable to predict response to chemotherapy in combination with 
bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). 
Methods:  
In 25 patients with advanced non-squamous NSCLC, 18F-FDG-PET/CT was performed before 
treatment and after two-weeks, at the end of the second week of first cycle carboplatin – 
paclitaxel and bevacizumab (CPB) treatment. Patients received up to a total of 4 cycles of 
CPB treatment. Maintenance treatment with bevacizumab monotherapy was continued until 
progressive disease without significant treatment related toxicities of first line treatment. In 
case of progressive disease bevacizumab was combined with erlotinib. Standardized uptake 
value (SUV) corrected for lean body mass (SUL and SULpeak) were obtained. PET response 
criteria in solid tumors (PERCIST) were used for response evaluation. These semi-
quantitative parameters were correlated with progression free survival (PFS) and overall 
survival (OS).  
Results:  
Metabolic response, defined by a significant reduction in SULpeak ≥30% after two weeks of 
CPB, was predictive of PFS and OS. For partial metabolic responders (n = 19) median OS 
was 22.8 mo. One year and 2-y OS were 79% and 47%, respectively. Non-metabolic 
responders (n = 6) (stable metabolic disease or progressive disease) showed a median OS of 
4.4 mo (1-y, and 2-y OS was 33% and 0% respectively) (P < 0.001). 
Conclusion:  
18F-FDG-PET/CT after one treatment cycle is predictive of outcome to first line chemotherapy 
with bevacizumab in patients with advanced non-squamous NSCLC. This enables 
identification of patients at risk of treatment failure, permitting treatment alternatives such as 
early switch to a different therapy. 
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Introduction 
 
Lung cancer is the major cause of cancer-related death in the Western World (1). Non-small cell lung 
cancer (NSCLC) represents about 80% of all lung cancer. In the majority of cases, patients already 
have locally advanced or metastatic disease at presentation. Vascular endothelial growth factor (VEGF) 
is an important mediator in tumor angiogenesis, which plays an important role in cancer cell survival in 
local tumor growth and in the development of distant metastases. A strongly increased expression of 
VEGF has been found in non–small-cell lung cancers (2) and is associated with an unfavorable impact 
on survival (3). Bevacizumab, a monoclonal antibody against VEGF-A, interacts with this pathway by 
blocking the effect of VEGF. A landmark phase 3 trail has shown that the addition of bevacizumab to 
carboplatin and paclitaxel in NSCLC improved overall survival (4). Recent American Society of 
Clinical Oncology guideline recommends adding bevacizumab to carboplatin plus paclitaxel (5). One 
explanation is that bevacizumab leads to vascular normalization of tumor vasculature (6), thus 
increasing delivery and of cytotoxic therapy to the tumor leading to increased treatment efficacy. The 
evaluation of tumor volume response by conventional imaging techniques using Response evaluation 
criteria in solid tumors (RECIST) criteria has its limitations in detection of early therapy response (7), 
especially in the case of targeted treatment. FDG-PET/CT provides rapid, non-invasive, in vivo 
assessment and quantification of glucose metabolism and might be a powerful tool for measurement of 
treatment response. Changes in tumor glucose metabolism precede changes in tumor size and can 
possibly reflect drug effects at a cellular level, resulting in a potential advantage over morphological 
imaging. Molecular imaging using FDG-PET/CT has shown in NSCLC patients to be a valuable tool 
for early detection of treatment response in chemotherapy (8), chemo-radiotherapy (9-13) and targeted 
treatment (14-19). The prediction of response using FDG-PET/CT may enable a distinction between 
patients who are going to benefit from treatment. An early detection of non-responders allows for 
treatment adaptation or earlier switch to other treatment lines. Ultimately, this can lead to a reduction in 
ineffective and potentially toxic therapy, a reduction in costs and a more personalized tumor-oriented 
approach. Few FDG-PET/CT response-monitoring studies have been performed to evaluate anti-
angiogenic treatment in NSCLC (20,21). To address this issue, a side-study for early FDG-PET/CT 
response monitoring study was performed, alongside a phase 2 trial in patients with newly diagnosed 
advanced NSCLC treated with first line chemotherapy carboplatin, paclitaxel and bevacizumab (CPB). 
We explored the value of FDG-PET/CT to predict clinical outcome by using an early in-treatment 
FDG-PET/CT. 
 
MATERIALS AND METHODS 
 
Patients 
From January 2009 to January 2013, patients with newly diagnosed locally advanced or metastatic 
NSCLC without prior systemic treatment were enrolled in this prospective single centre study. Patients 
with histologically or cytologically confirmed non-squamous NSCLC (stage IIIB or stage IV) and at 
least one measurable lesion (based on RECIST 1.1) were eligible. Exclusion criteria were previous 
chemotherapy or systemic anti-tumor therapy, previous radical radiotherapy, performance score ≥2 
(Eastern Co-operative Oncology Group) or another active malignancy except for non-melanoma skin 
cancers in the last 5 years. This study was approved by the institutional review Board of the Radboud 
university medical center Nijmegen. All patients provided written informed consent. 
 
Treatment 
Patients were treated with bevacizumab (15 mg/kg every three weeks), paclitaxel (200 mg/m2 body 
surface area on day 1 every three weeks) and carboplatin (area under concentration time curve of 6, on 
day 1 every 3 weeks). Patients received a maximum of 4 cycles of therapy, after which monotherapy of 
bevacizumab was continued as long as patients had no evidence of progressive disease and no 
significant treatment related toxicities. In case of progressive disease bevacizumab 15 mg/kg every 3 
weeks continued and erlotinib 150mg/day (second line treatment) added. Both epidermal growth factor 
receptor (EGFR) mutated and EGFR wild type genotypes were included in the study. 
 
Study design 
Primary objective of this phase II study was to monitor the efficacy of erlotinib plus bevacizumab (BE) 
subsequent to progressive disease on CPB as determined by the maximum achieved disease control 
rate. One of the secondary objectives was determination of early response and FDG-PET/CT was 
performed before treatment and after 1 cycle of treatment (before the second cycle of treatment). Other 
secondary objectives were to monitor disease control rate and time to progression of CPB and BE 
respectively, and overall survival. The study design is shown in Figure 1. Clinicians were blinded to 
the results of the in-treatment FDG-PET/CT. Standard clinical response evaluation was done using 
contrast enhanced computed tomography (CT) at every 6 weeks until disease progression. Response 
was assessed according to RECIST 1.1 (22) every 6 weeks (or every 9 weeks after week 18 in the BE 
treatment phase), at onset of clinical signs of progression and in case of premature discontinuation of 
study treatment. Partial response (PR) or complete response, had to be confirmed after a minimum of 4 
weeks. In case of stable disease (SD), follow-up measurements must have met the stable disease 
criteria at least once after study entry at a minimal interval of 6 weeks.  
 
FDG-PET/CT 
For each patient baseline and in-treatment FDG-PET/CT were performed with the same hybrid 
PET/CT scanner (Siemens Biograph Duo or Siemens Biograph 40 mCT, Siemens Medical Solutions 
USA, Inc.) according to the guidelines of the European Association of Nuclear Medicine (23). At least 
6 hours before 18F-FDG injection, the patients fasted, including discontinuation of any tube or PEG-
feeding and any glucose-containing i.v. fluids. Immediately before 18F-FDG injection, the blood 
glucose level was checked. According to protocol FDG-PET/CT scans were performed at mean 66 
minutes (range 58 – 73) after 18F-FDG injection and furosemide 10 mg, covering the neck, thorax, 
abdomen and pelvis. The PET acquisition time was 4 minutes per bed position. PET scans from the 
Siemens Biograph Duo were processed using iterative reconstruction with the ordered subsets 
expectation maximization algorithm (image matrix size, 128 x 128, 4 iterations, 16 subsets; and a 5-
mm 3-dimensional Gaussian filter). PET images from the Siemens Biograph 40 mCT were 
reconstructed with the TrueX algorithm (with a spatially varying point spread function and the 
incorporation of time-of-flight measurements (Ultra-HD PET). Image reconstruction was performed 
with three iterations, 21 subsets, and a matrix size of 400×400 (pixel spacing of 2.04 mm). 
Reconstructed images were corrected for injected dose, decay of 18F-FDG, patient body weight, and 
attenuation using a low-dose CT scan. Correction for breathing motion using a 4D mode was not used. 
 
Analysis of FDG-PET 
FDG-PET/CTs were analyzed on Pinnacle3 (version 8.0d; Philips Radiation Oncology Systems). At 
baseline, FDG-PET/CT was analyzed visually (number and localization of lesions) and quantitatively. 
SUV was normalized by lean body mass using Janmahasatian formula (24). The SULpeak of target 
lesions at baseline was at least 1.5× mean liver SUL + 2 standard deviations of mean SUL. At follow-
up, FDG-PET/CT was analyzed visually (number and localization of lesions, new lesions, visual 
change in uptake and size) and quantitatively (SUV, SUL, SULpeak). A maximum of five target lesions 
were selected and delineated using a 50% iso-contour threshold, according to PERCIST criteria (up to 
a maximum of two lesions per organ). New FDG-avid lesions, suspect for metastasis, were considered 
progressive disease. For evaluation of response predefined response criteria (PERCIST criteria) were 
used (25): A complete metabolic response (CMR) was defined as a complete resolution of FDG-uptake 
within the measurable target lesions and other lesions (less than mean liver activity and at the level of 
surrounding background blood pool activity) without the advent of new suspicious FDG-avid lesions. 
Partial metabolic response (PMR) was defined as a reduction of ≥30% in the target tumor SULpeak (and 
an absolute drop of at least 0.8 SUL). PMD was a ≥30% increase in SULpeak or advent of new FDG-
avid lesions typical of cancer. Stable metabolic disease (SMD) (reduction < 30% and increase < 30%) 
was disease other than CMR, PMR or PMD. Two independent readers, blinded to the results of the CT-
scans, performed reading of the FDG-PET/CTs and vice versa.  
 
Statistical analysis 
Patients were considered evaluable for analysis if they underwent both pre-treatment FDG PET/CT and 
in-treatment FDG PET/CT. OS was measured from the date of treatment start to time to disease related 
death. PFS was measured from the date of treatment start to time of disease progression on contrast 
enhanced CT. In-treatment response evaluation on CT was measured at 6-weeks after treatment start. 
On FDG-PET/CT (measured 2 weeks in-treatment) metabolic response was defined as CMR or PMR 
and metabolic non-response was defined as SMD or PMD. Concordance between in-treatment 
PERCIST and RECIST was assessed using Cohen’s κ coefficient and Wilcoxon’s signed-ranks test. OS 
and PFS survival analysis was performed using Kaplan-Meier-method. Responders and non-responders 
were compared using log-rank statistics. Statistical analysis was performed using SPSS 22.0 (SPSS 
Inc.) for Windows (IBM Corp, Armonk, NY). The level of statistical significance was defined as a P < 
0.05 based on two sided tests. No time-dependent adjustment was needed, because no progression or 
death was observed before the RECIST assessment.  
 
RESULTS 
 
Patients Characteristics and Follow-up 
Thirty-two patients were enrolled in the phase 2 study, of which 26 patients had a baseline FDG-
PET/CT. Patient characteristics are shown in Table 1. One patient did not receive in-treatment FDG-
PET/CT after the first treatment cycle and therefore was excluded from further analysis. Of the 
remaining 25 patients, 22 patients (88%) received 4 cycles (out of 4) CBP, while three patients (12%) 
received only 2 cycles first line treatment, due to early disease progression. 21 patients (84%) 
continued monotherapy bevacizumab. 19 patients (76%) received second line treatment of erlotinib 
plus bevacizumab after they progressed on (CP)B. One patient receiving second line erlotinib and 
bevacizumab had an EGFR mutation. In the present study an EGFR mutation was found in two 
patients. Baseline FDG-PET/CT was always performed before treatment; median time of baseline 
FDG-PET/CT was 13 days (range 2 – 35d) before treatment. There was no relation between delay on 
treatment start and outcome (PFS or OS) in Cox proportional hazards analysis (hazard ratio of 0.997 
(0.963 – 1.033) (P=0.871) for OS and hazard ratio of 0.987 (0.952 – 1.023) for PFS (P = 0.470). The 
in-treatment FDG-PET/CT was performed after 1 cycle of treatment at day 14 (13 – 20 d), always 
before the second cycle of treatment. Median time to second line treatment was 9.3 months (range 1.4 – 
21.9). Kaplan Meier analysis for PFS and OS stratified using RECIST (6-weeks after treatment start) is 
shown in Figure 2, no significant difference between response groups was found (log-rank P = 1.000 
and P = 0.468 for PFS and OS, respectively). During follow-up all 25 patients died due to disease 
progression. 
 
Predictive value of FDG-PET/CT 
Median baseline SUV was 6.8 and after 15 days of CPB treatment median SUV was 5.0 in the target 
lesions. In all cases SUL versus SUV response categories (using same cut off levels of 30%) were 
100% concordant. According to PERCIST no patient had CMR, 2 (8%) patients had PMD, while 4 
(16%) patients had stable metabolic disease (SMD). 19 (76%) patients had PMR. For non-responders 
(both PMD and SMD) median PFS was 1.7 months (range 1.0 – 6.1 mo). For patients with PMR 
median PFS was 8.7 months (range 3.7 – 35.7 mo), 1-y and 2-y PFS were 21% and 5%, respectively. 
For SMD and PMD median OS was 4.4 months (range 1.7 – 14.1 mo); 1-y, and 2-y OS was 33% and 
0% respectively. For PMR median OS was 22.8 months (range 4.3 – 54.6 mo), 1-y and 2-y OS were 
79% and 47%, respectively. The Kaplan-Meier analysis of PFS and OS stratified using PERCIST is 
shown in Figure 3. Figure 4 and 5 show two examples of patients with stage IV disease, with their 
baseline and in-treatment FDG-PET/CT.  
 
Comparison of treatment response between RECIST and PERCIST 
Nineteen patients were classified as SD on CT (6-weeks in-treatment), while 4 patients were classified 
as SMD according to FDG-PET/CT. 15 patients were classified as PMR. RECIST and PERCIST 
classifications are shown in Table 2. PERCIST and RECIST were discordant in 16 patients (64%). Of 
the 19 patients having SD according to RECIST, 14 patients were reclassified as having PMR 
according to PERCIST. One patient was classified as PMD due to the advent of new FDG-avid lesions 
suspected of bone metastasis, however these lesions were not detected on the 6-week in-treatment CT 
(this patient died 52 days after treatment start). Cohen’s coefficient κ = 0.023 was indicating minimal 
agreement between RECIST and PERCIST. Wilcoxon’s signed-ranks test was P<0.01 indicating 
significant difference between RECIST and PERCIST. 
 
DISCUSSION 
This prospective study showed that early in-treatment FDG-PET/CT in advanced NSCLC after two 
weeks of first chemotherapy and bevacizumab is predictive of PFS and OS. Compared to CT, PET 
detected response earlier during treatment and more frequently. Therefore, the predictive potential of 
an early in-treatment FDG-PET/CT, performed at two weeks after start of treatment, is better than 
measurement of size changes on CT according to RECIST at 6 weeks after start of treatment. This 
resulted in discordance between PERCIST and RECIST in 16 patients (64%). These differences can 
only partially be explained by the difference in timing of the response evaluation of FDG-PET/CT (2 
weeks in-treatment) and diagnostic CT (6 weeks in-treatment). Early after treatment initiation, tumor 
size changes as a result of, both tumor reduction (i.e. mitotic cell death and cell loss) and tumor growth 
(i.e. cell division). As a result, small size changes, i.e. actual response or actual tumor growth or 
progression are underestimated when tumor size is used as an early predictive marker. According to 
PERCIST, a significant reduction in FDG-uptake after one treatment cycle was associated with 
favourable outcome in terms of both PFS and OS. In this study, 6 out of 25 patients (24%) were 
classified as non-responder (SMD or PMD), showing significantly lower median OS and PFS when 
compared to patients with a PMR (P < 0.001). Of the 19 patients having SD according to RECIST, 14 
patients were reclassified as having PMR according to PERCIST, showing that metabolic changes 
exceeded the threshold criteria earlier than morphological changes. A prospective study by Shang et al. 
(26) comparing RECIST, EORTC and PERCIST criteria for evaluation of early response (after two 
weeks) to chemotherapy in NSCLC patients showed that both EORTC and PERCIST criteria were 
more accurate in predicting an early response to treatment. 
 
Studies addressing response prediction in advanced NSCLC treated with first line chemotherapy and 
bevacizumab are limited. De Langen et al. (21) demonstrated in (locally) advanced NSCLC patients 
treated with erlotinib and bevacizumab that a decrease in SUV of more than 20% after three weeks was 
associated with increased progression free survival. In oncology practice it is important to identify 
effective biomarkers for prediction of failure or success of treatment. In contrast to our study, other 
response-monitoring studies (9-14) did not use PERCIST criteria for response evaluation (25). 
Predefined response criteria, are not only important tools to assess an objective early response, but are 
also important in harmonization of FDG-PET/CT studies and facilitate reproducibility across response 
assessment trials.  
 
Major concern during anti-VEGF treatment is tumor evasion and resistance from VEGF blockage, 
involving several possible escapes mechanisms (27). An apparent increase in FDG-uptake during 
treatment might suggest resistance mechanisms resulting in an increase in anaerobic metabolism and an 
increase in glycolysis. Alternatively, the decrease of tumor vascularity due to anti-angiogenic agents 
could also lead to an increase in hypoxia and glycolysis. However, 18F-FDG alone is not capable of 
discriminating between hypoxic and non-hypoxic regions. Tumor hypoxia and metabolism are 
independent events, which was shown in a study comparing 18F-FAZA and 18F-FDG in NSCLC (28). 
The effects of anti-angiogenic treatment could negatively affect the efficacy of FDG-PET/CT early 
response monitoring in NSCLC. However, in our report we show that early response monitoring in 
NSCLC patients treated with chemotherapy the addition of bevacizumab seems feasible. Another 
entirely different approach is 89Zr-bevacizumab to visualise targeting of VEGFR for prediction of 
treatment efficacy (29), however further studies are need to establish a potential role for 89Zr-
bevacizumab in NSCLC.  
 
A limitation of our study is the relative small number of patients. For development of a clinical 
application of metabolic treatment response studies, larger series are necessary. In our analysis PMD 
and SMD patients were defined as non-metabolic responders. These two categories may have outcome 
differences can only be detected by a much lager study population. When effective surrogates for early 
prediction are established, treatment decision-making based on the early in-treatment FDG-PET/CT 
seems feasible. In our study we showed that as early as 2 weeks into first line treatment, early 
metabolic changes predict clinical outcome. The majority of other FDG-PET/CT response assessments 
studies were performed at relative late time-point during treatment, not allowing any treatment 
adaptation based on the response assessment (30-32). Early discontinuation of ineffective treatment 
regimen can possibly prevent unnecessary treatment toxicity. Moreover, earlier switch to a potentially 
beneficial different therapy could result in early tumour consolidation, better outcomes and better cost-
effectiveness.  
 
Another limitation of our study is the second line bevacizumab and erlotinib therapy started after 
progression on CPB or on bevacizumab maintenance. This investigational second line approach (given 
in 76% of the patients) showed only modest clinical benefit (33), where OS and PFS on first line CPB 
were in line with published data (4). However, the optimal strategy of anti-angiogenic therapy in the 
treatment of advanced NSCLC is still subject to randomized trials and large observational studies. 
Continuation of bevacizumab treatment in the absence of disease progression is a new treatment 
strategy in NSCLC, which is less toxic than traditional chemotherapy agents (34) and well tolerated 
(35). The concept of continuing bevacizumab treatment beyond progression is under investigation (36). 
More recently, the role of erlotinib with bevacizumab as first-line therapy is being explored (37).  
 
CONCLUSION 
 
The current study in advanced non-squamous NSCLC patients treated with first line chemotherapy and 
bevacizumab showed that early in-treatment FDG-PET/CT is predictive of response to treatment and 
overall survival, already after two weeks of therapy. This enables identification of patients at risk of 
treatment failure, permitting an early and more individualized treatment modification. 
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FIGURE 1. Study design. 
 
TABLE 1 
Patient Characteristics  
Characteristics Value 
Median age (y) (range) 54 (42 - 81) 
Gender  
    Male 15 (47%) 
    Female 17 (53%) 
EGFR mutation status 
   EGFR mutation 
   No EGFR mutation 
 
2   (6%) 
30 (94%) 
TMM-stage (7th edition)  
    IIIB 1   (4%) 
    IV 31 (96%) 
Smoking status  
    Current smoker 15 (47%) 
    Former smoker 17 (53%) 
Previous malignancy  
    No 6   (19%) 
    Yes 26 (81%) 
CPB treatment cycles 
    <4 
    4 
 
6   (19%) 
26 (81%) 
Maintenance bevacizumab cycles 
    0 
    ≥ 1 
 
6   (19%) 
26 (81%) 
BE maintenance cycles 
    0 
    ≥ 1 
 
11 (34%) 
21 (66%) 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2 
Comparison of in-treatment response between PERCIST and RECIST 
 
 
 
 
PERCIST 
 RECIST 
CR (n = 0) PR (n = 6) SD (n = 19) PD (n = 0) 
CMR (n = 0) 0 0 0 0 
PMR (n = 19) 0 5 14 0 
SMD (n = 4) 0 1 3 0 
PMD (n = 2) 0 0 2 0 
     
  
FIGURE 2. Kaplan-Meier analysis of PFS and OS stratified using RECIST. For SD median 
PFS was 8.4; median OS was 14.5 months; For PR median PFS was 7.4 months; median OS 
was survival was 17.6 months. Log-rank test, P = NS. 
 
 FIGURE 3. Kaplan-Meier analysis of PFS and OS stratified using PERCIST criteria. For SMD 
and PMD median PFS was 1.7 months; median OS was 4.4 months; For PMR median PFS 
was 9.1 months; OS was 22.8 months; Log-rank test, P < 0.001. 
  
 
FIGURE 4. Baseline (A) and in-treatment (B) FDG-PET/CT in a 51-year-old female patient 
with NSCLC, stage IVB, with a Pancoast tumor in the left lung with metastasis in the right 
adrenal gland (white and black arrows). In-treatment FDG-PET/CT showed apparent 
decrease in uptake classified as partial metabolic response. Survival was 12.4 months. 
 
FIGURE 5. Baseline (A) and in-treatment (B) FDG-PET/CT in a 67-year-old female patient 
with NSCLC, stage IVB, with a tumor in the left lower lobe with metastases in lymph nodes, 
lung, liver and bones. In-treatment FDG-PET/CT showed apparent increase in uptake (open 
arrows) and new FDG-avid bone lesions (black arrows), classified as progressive metabolic 
disease. Survival was 1.7 months. 
 
 







